What Fennec Pharmaceuticals Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 5 | 19 |
| Total trades | 29 | 103 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 69,279 | 468,369 |
| Disposed | 122,545 | 1,488,063 |
| Net activity | −53,266 | −1,019,694 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Cioffi Christiana Marie | Chief Strategy Officer | Oct 12 | Grant / award · A | +3,946 | $5.53 | +$21.8K | 28,746 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | Oct 12 | Grant / award · A | +3,846 | $5.53 | +$21.3K | 246,855 |
| Hackman Jeffrey S. | Chief Executive Officer | Oct 12 | Grant / award · A | +2,224 | $5.53 | +$12.3K | 69,685 |
| Sayad Pierre Sargis | Chief Medical Officer | Oct 12 | Grant / award · A | +3,846 | $5.53 | +$21.3K | 13,533 |
| Evans Terry L | Chief Commercial Officer | Oct 12 | Grant / award · A | +2,326 | $5.53 | +$12.9K | 24,013 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | Sep 30 | Grant / award · A | +1,703 | — | — | 243,009 |
| Sayad Pierre Sargis | Chief Medical Officer | Sep 30 | Grant / award · A | +168 | — | — | 9,687 |
| Hackman Jeffrey S. | Chief Executive Officer | Sep 30 | Grant / award · A | +1,159 | — | — | 67,461 |
| Cioffi Christiana Marie | Chief Strategy Officer | Sep 30 | Grant / award · A | +156 | — | — | 24,800 |
| Evans Terry L | Chief Commercial Officer | Sep 30 | Grant / award · A | +168 | — | — | 21,687 |
| Brughera Marco Maria | Director | Sep 15 | Disclosed 10b5-1 sale · S | −15,545 | $10.29 | −$160K | 0 |
| Brughera Marco Maria | Director | Sep 15 | Exercise / conversion · M | +15,545 | $2.11 | +$32.8K | 15,545 |
| Raykov Rosty | Insider | Sep 01 | Disclosed 10b5-1 sale · S | −10,000 | $12.11 | −$121K | 124,411 |
| Raykov Rosty | Insider | Aug 31 | Grant / award · A | +2,778 | — | — | 134,411 |
| Sayad Pierre Sargis | Chief Medical Officer | Aug 31 | Open-market sale · S | −12,000 | $12.18 | −$146K | 9,519 |
| Sayad Pierre Sargis | Chief Medical Officer | Aug 31 | Grant / award · A | +168 | — | — | 21,519 |
| Evans Terry L | Chief Commercial Officer | Aug 31 | Grant / award · A | +168 | — | — | 21,519 |
| Cioffi Christiana Marie | Chief Strategy Officer | Aug 31 | Grant / award · A | +156 | — | — | 24,644 |
| Hackman Jeffrey S. | Chief Executive Officer | Aug 31 | Grant / award · A | +1,159 | — | — | 66,302 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | Aug 31 | Grant / award · A | +1,703 | — | — | 241,306 |
Loading...
